These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3938472)

  • 1. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N; Yamamoto M; Takayama H
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
    Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
    Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract]   [Full Text] [Related]  

  • 4. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
    Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease].
    Narabayashi H; Yokochi F; Ogawa T; Igakura T
    No To Shinkei; 1991 Mar; 43(3):263-8. PubMed ID: 1907469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
    Yamamoto M; Ogawa N; Ujike H
    J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of L-threo-DOPS on P-300 in parkinsonism].
    Yokota J; Itoh T; Imai H; Narabayashi H
    Rinsho Shinkeigaku; 1990 May; 30(5):499-504. PubMed ID: 2119267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
    Fukada K; Endo T; Yokoe M; Hamasaki T; Hazama T; Sakoda S
    Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pure akinesia presenting with antecollis].
    Ota S; Tsuchiya K
    No To Shinkei; 2005 Oct; 57(10):893-8. PubMed ID: 16277235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
    Ujike H; Yamamoto M
    J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
    Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
    Yamamoto M; Ujike H; Ogawa N
    Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W; Birkmayer G; Lechner H; Riederer P
    J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the metabolism of droxidopa in humans].
    Maruyama W; Naoi M; Narabayashi H
    Rinsho Shinkeigaku; 1994 Oct; 34(10):991-5. PubMed ID: 7834960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
    Yoshida M; Noguchi S; Kuramoto S
    Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Synthesis of norepinephrine from 3,4-dihydroxyphenylserine by L-aromatic amino acid decarboxylase of the rat brain and kidneys].
    Fujiwara H; Inagaki C; Ikeda Y; Tanaka C
    Nihon Yakurigaku Zasshi; 1976 Oct; 72(7):891-8. PubMed ID: 14060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
    Narabayashi H
    No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
    [No Abstract]   [Full Text] [Related]  

  • 20. Beneficial attenuating effect of L-threo-3,4-dihydroxyphenylserine on postural hypotension in anesthetized rats.
    Satoh S; Oyabe A; Tanno M; Suzuki-Kusaba M
    Arzneimittelforschung; 1989 Sep; 39(9):1123-9. PubMed ID: 2511849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.